2025 EASL Congress Spotlight: CG-0416 Preclinical Data Unveils A Groundbreaking Dual-Action Therapy Targeting Obesity and MASH ...Middle East

——A First-in-Class Hydrolysis-Activated Liver-Targeted THR-β Prodrug Demonstrating A Dual Advantage of Fat Reduction and Muscle Preservation SHANGHAI, May 16, 2025 /PRNewswire/ -- At the European Association for the Study of the Liver (EASL) Annual Congress, CureGene Pharmaceuticals...

Read More Details
Finally We wish PressBee provided you with enough information of ( 2025 EASL Congress Spotlight: CG-0416 Preclinical Data Unveils A Groundbreaking Dual-Action Therapy Targeting Obesity and MASH )

Also on site :

• Oscar Winner Stuns On The Red Carpet As The Cannes ‘Godmother’ — What The Prestigious Title Means
• Yet another docu-series about Deion Sanders is currently in the works
• Food Network Star Teases Major Career Venture